Position in ABVX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,889,309
-$5,379,595 QoQ
Shares Held
25,948
-57.7% QoQ
Ownership
0.030%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABVX Over Time
Shares Held
Position Value (USD)
Derivatives in ABVX
reported options exposure · as of Mar 31, 2026CallValue
$579,020
CallShares
5,200
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Verition Fund Management LLC holds $52,210,876 across 39 Biotechnology names. ABVX ranks #5 (5.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EVMN |
Evommune, Inc.
|
549,991 | $12,644,293 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
110,000 | $10,697,500 | |
| 3 | OCUL |
Ocular Therapeutix, Inc
|
527,338 | $4,466,552 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
|
55,000 | $3,198,250 | |
| 5 | ABVX |
Abivax S.A.
This page
|
25,948 | $2,889,309 | |
| 6 | TECH |
BIO-TECHNE Corp
|
53,519 | $2,796,902 | |
| 7 | MLYS |
Mineralys Therapeutics, Inc.
|
95,122 | $2,576,854 | |
| 8 | TBPH |
Theravance Biopharma, Inc.
|
110,000 | $1,785,300 |
All Filings in ABVX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $579,020 | 5,200 | Call | Sole | 2026-05-15 | |
| 2026-03-31 | $2,889,309 | 25,948 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $8,268,904 | 61,317 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $4,806,868 | 56,618 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||